3 Oncology Generics, Acute Therapy Franchise and Pain and Anti-Malarial Brands Stocks With a Strong Future Roadmap: Natco Pharma, Alkem Laboratories and Ipca Laboratories

Complex generic and pain care stocks let investors follow companies that combine hard-to-copy generics with well-known domestic brands. Natco Pharma, Alkem Laboratories and Ipca Laboratories cover oncology generics, an acute therapy franchise, and pain and anti-malarial brands.

This list covers three complex generic and pain care stocks with complete current figures: Natco Pharma, Alkem Laboratories and Ipca Laboratories. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Complex Generic and Pain Care Stocks?

Complex generic and pain care stocks are listed pharmaceutical companies that sell complex generics abroad and leading brands in acute therapies at home. Their earnings depend on approvals, launches and prescription trends.

Complex Generic and Pain Care Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing complex generic and pain care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Complex Generic and Pain Care Stocks Have a Strong Roadmap in India?

Complex generic and pain care stocks have a strong roadmap in India because rising demand for acute care at home and for complex generics abroad supports steady growth for established players.

• Complex products. Hard-to-make generics face fewer competitors.
• Acute care demand. Brands in pain and infection care see recurring prescriptions.
• Wider access. Better reach brings medicines to smaller towns.

Why Natco Pharma Features Among These Complex Generic and Pain Care Stocks

Among the complex generic and pain care stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Why Alkem Laboratories Features Among These Complex Generic and Pain Care Stocks

Among the oncology generic shares on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.

In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.

Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.

Roadmap: Alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.

What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.

Why Ipca Laboratories Features Among These Complex Generic and Pain Care Stocks

Among the three companies on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Natco Pharma vs Alkem Laboratories vs Ipca Laboratories on Key Financials

The table below sets the three complex generic and pain care stocks side by side on revenue, profit and margin, using reported figures.

Alkem Laboratories posts the highest return on equity in this group at 16.7%. Alkem Laboratories has the largest FY26 revenue at Rs 15,296 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with complex generic and pain care stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Complex Generic and Pain Care Stocks

Every theme carries risks that deserve a check before any decision. For these complex generic and pain care stocks, the main points are: Long-term oncology generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing rules. Price controls can limit the pace of growth for some medicines.
• Approval timelines. Launches depend on regulatory decisions that can shift.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter complex generic and pain care stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Complex Generic and Pain Care Stocks

Complex generic and pain care stocks reward investors who follow approvals, launches and prescription trends together. Natco Pharma, Alkem Laboratories and Ipca Laboratories each bring a strong franchise. Based on the 21 October 2026 close, Natco Pharma trades at Rs 784.45, Alkem Laboratories at Rs 5,015 and Ipca Laboratories at Rs 1,918.9.

Download the Univest iOS App or Univest Android App to track complex generic and pain care stocks, set price alerts and get research-backed stock ideas.

What are complex generic and pain care stocks?

Ans. Complex generic and pain care stocks are listed pharmaceutical companies that sell complex generics abroad and leading brands in acute therapies at home. Their earnings depend on approvals, launches and prescription trends. This list looks at three of them, Natco Pharma, Alkem Laboratories and Ipca Laboratories, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which complex generic and pain care stocks are covered in this list?

Ans. This list covers Natco Pharma, Alkem Laboratories and Ipca Laboratories. Based on the 21 October 2026 close, Natco Pharma traded at Rs 784.45, Alkem Laboratories at Rs 5,015 and Ipca Laboratories at Rs 1,918.9. Their return on equity ranges from 14.2% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 21.0%.

Why do complex generic and pain care stocks have a strong future roadmap in India?

Ans. Complex generic and pain care stocks have a strong roadmap in India because rising demand for acute care at home and for complex generics abroad supports steady growth for established players. The main drivers are as follows. Complex products. Hard-to-make generics face fewer competitors. Acute care demand. Brands in pain and infection care see recurring prescriptions. Wider access. Better reach brings medicines to smaller towns. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

How has Alkem Laboratories performed financially?

Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What risks should investors check before buying complex generic and pain care stocks?

Ans. Investors should check a few risks before buying complex generic and pain care stocks. Pricing rules. Price controls can limit the pace of growth for some medicines. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of complex generic and pain care stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.